CIBC Bancorp USA’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.15M Buy
17,523
+6,062
+53% +$462K ﹤0.01% 1075
2026
Q2
$976K Buy
11,461
+1,362
+13% +$97.8K ﹤0.01% 1107
2026
Q1
$666K Buy
+10,099
New +$642K ﹤0.01% 1145
2025
Q3
$684K Buy
+12,453
New +$513K ﹤0.01% 761

Other funds holding CYTK

CIBC Bancorp USA's CYTK Position: Q3 2026 in Review

CIBC Bancorp USA increased its Cytokinetics (CYTK) stake by 53% in Q3 2026, buying an estimated $462K and bringing the position to 17,523 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1075.

CIBC Bancorp USA first reported a position in CYTK in Q3 2025 and has held it in 4 quarters since. 468 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

  • CIBC Bancorp USA held 17,523 shares of Cytokinetics worth $1.15M as of Q3 2026.
  • CIBC Bancorp USA bought 6,062 Cytokinetics shares in Q3 2026, an estimated $462K.
  • Cytokinetics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1075 holding.
  • CIBC Bancorp USA first reported a position in Cytokinetics in Q3 2025 and has held it in 4 quarters since.
  • 468 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.